Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH103 in Relapsed/Refractory B-ALL
NCT06056752Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Sep 2023
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QH103E in B cell acute lymphoblastic leukemia (B-ALL), sponsored by The First Affiliated Hospital of USTC. Primary endpoints: Incidence of Adverse Events (AEs) at 12 months, Incidence of Dose-Limiting Toxicities (DLTs) at 28 days and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
QH103E
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06056752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06056752.